logo image
  • News
    • People Moves
    • Deal Wins
    • Demand Drivers
    • M&A and Funding
    • Financial Results
    • Technology
    • Academia
    • Industry News
    • Features
    • Machine Translation
    • — Divider —
    • Slator Pro
    • — Divider —
    • Press Releases
    • Sponsored Content
  • Data & Research
    • Research Reports & Pro Guides
    • Language Industry Investor Map
    • Real-Time Charts of Listed LSPs
    • Language Service Provider Index
  • Podcasts & Videos
  • Events
    • Design Thinking – February 2021
    • — Divider —
    • SlatorCon Coverage
    • Other Events
  • Directory
  • RFP Center
  • Jobs
MENU
  • News
    • People Moves
    • Deal Wins
    • Demand Drivers
    • M&A and Funding
    • Financial Results
    • Technology
    • Academia
    • Industry News
    • Features
    • Machine Translation
    • — Divider —
    • Slator Pro
    • — Divider —
    • Press Releases
    • Sponsored Content
  • Data & Research
    • Research Reports & Pro Guides
    • Language Industry Investor Map
    • Real-Time Charts of Listed LSPs
    • Language Service Provider Index
  • Podcasts & Videos
  • Events
    • Design Thinking – February 2021
    • — Divider —
    • SlatorCon Coverage
    • Other Events
  • Directory
  • RFP Center
  • Jobs

Advertise on Slator! Download the 2021 Online Media Kit Now

  • Slator Market Intelligence
  • Slator Advertising Services
  • Slator Advisory
  • Login
Search
Generic filters
Exact matches only
Advertisement
Takeaways: Slator’s Roundtable on Compliance and Vendor Management in Clinical Trials

4 years ago

April 4, 2017

Takeaways: Slator’s Roundtable on Compliance and Vendor Management in Clinical Trials

Sponsored Content ·

by Eden Estopace

On April 4, 2017

4 years ago
Sponsored Content ·

by Eden Estopace

On April 4, 2017

Takeaways: Slator’s Roundtable on Compliance and Vendor Management in Clinical Trials

If you ask the World Health Organization (WHO), the global response to public health emergencies isn’t fast enough. This is not only about pandemics like the zika or ebola virus which can spread like wildfire across national borders with devastating consequences. Diseases also develop and spread faster today and require faster response from governments and health organizations.

The life sciences sector is in a bind. While there is an adequate pipeline of medicines under development (over 240,000 clinical studies across countries are listed on Clinicaltrials.gov), major challenges affect the speed of bringing these drugs into full development, starting off with bottlenecks in doing clinical trials.

A recent study conducted by Lionbridge identified the top issues in clinical trials – delays in patient recruitment, increased regulatory guidelines, compliance and vendor management issues, and global language challenges, particularly in culturally sensitive regions like the Asia-Pacific.

Advertisement

Slator gathered industry experts in Singapore on March 30, 2017 to discuss these issues in greater detail and foster a better understanding of the challenges ahead. Participants included senior executives from leading life sciences companies such as Anidan Group, Alcon, Astellas, Elsai, EPS International, Gsk, INC Research, Johnson and Johnson, Lundbeck Singapore, Novartis Asia-Pacific, PRA, PRAHS, Sandoz, Sanofi, Takeda Development Center Asia and Vifor Pharma.

The roundtable was sponsored by Lionbridge, one of the largest global providers of language translation and localization services for the life sciences industry. Maija Burtmanis, an Australian qualified senior Legal/Compliance Life Sciences Professional, who led the discussions, emphasized at the beginning of the presentation that only four countries in Asia-Pacific have English as a first language. This makes bilingual translation, interpretation of key data, and compliance to regulatory guidance absolutely critical.

Burtmanis has worked as a senior lawyer and compliance professional for Pfizer, Novartis and Johnson & Johnson and has covered jurisdictions including Russia, Japan, China, India and the breadth of Asia-Pacific.

“From a legal perspective, if there is one thing we must be concerned about, it is how to get the interpretation of the language right,” she said.

As conducting clinical trials across different locations often include working with third parties such as contract research organizations (CROs), the process requires a robust structure for success. A participant highlighted the fact that a global company working in the local China market may be constrained to work with local companies working in local Chinese protocols only and have to use English translation services.

“There needs to be a good systems in place,” Burtmanis affirmed, emphasizing that the risk universe is large. Beyond the language issues, there have been developments in recent years around regulations and compliance, especially in China, that are also throwing a curved ball on multinational as well as local organizations.

The recent move of the Chinese government, for example, to kickstart the health sector by subsidizing domestic R&D, strengthening IP rules and enforcement, establishing biotech parks, and encouraging big pharma to invest and set up R&D facilities (with tax breaks), appear to be good news at face value. However, it is forcing a rethink among global companies, and even local firms.

With the incentives in place, is it a good time to partner now with local CROs? Maya said the whole point is that China wants to create a dynamic innovation hub within this region and it is leading way in appealing to industries, particularly the tech and life sciences and automation sectors, to encourage them to have the confidence in putting their money in China. But can the locals keep up with international standards?

“From a legal perspective, if there is one thing we must be concerned about, it is how to get the interpretation of the language right” — Maija Burtmanis, Senior Legal/Compliance Life Sciences Professional

And when the China Food and Drug Administration (CFDA) introduced in July 2015 a circular mandating the self-inspection of clinical trial data to encourage multinational and even local companies to self-inspect their own trials, warning of surprise audits and harsh consequences for those who fail to comply with standards, it has also led many multinational companies in the US or Europe to question their confidence in their own CROs.

“Companies are taking it seriously. So the world of clinical development, regulatory compliance has become extremely important,” Burtmanis said. “Many companies have initiated their own self-inspections.”

However, as many participants have shared, this development has also triggered voluntary withdrawals from projects from local CROs, knowing that they wouldn’t be able to comply with the standards. “So the situation now is that you lack qualified CROs to do the job,” one participant said.

The point is, big and small players must do due diligence. “A lot of it comes down  to selecting the providers with the track record and the experience,” Burtmanis concluded.

Download our media kit and learn more about Slator’s Executive Roundtables.

TAGS

clinical trialslife sciences
SHARE
Eden Estopace

By Eden Estopace

IT journalist and Online Editor at Slator. Loves books, movies, and gadgets; writes for a living, but codes for fun.

Advertisement

SUBSCRIBE TO THE SLATOR WEEKLY

Language Industry Intelligence
In Your Inbox. Every Friday

SUBSCRIBE

SlatorSweepSlatorPro
ResearchRFP CENTER

PUBLISH

PRESS RELEASEDIRECTORY LISTING
JOB ADEVENT LISTING

Bespoke advisory including speaking, briefings and M&A

SLATOR ADVISORY
Advertisement

Featured Reports

See all
Slator 2020 Language Industry M&A and Funding Report

Slator 2020 Language Industry M&A and Funding Report

by Slator

Slator 2021 Data-for-AI Market Report

Slator 2021 Data-for-AI Market Report

by Slator

Slator 2020 Medtech Translation and Localization Report

Slator 2020 Medtech Translation and Localization Report

by Slator

Pro Guide: Sales and Marketing for Language Service Providers

Pro Guide: Sales and Marketing for Language Service Providers

by Slator

Press Releases

See all
iDISC Awarded ISO 27001 Information Security Management Certification

iDISC Awarded ISO 27001 Information Security Management Certification

by iDISC

XTRF Launches a Bi-Monthly Free Networking Event for Localization Professionals

XTRF Launches a Bi-Monthly Free Networking Event for Localization Professionals

by XTRF

150 Million Words Translated: the German EU Council Presidency Translator Sets New Records

150 Million Words Translated: the German EU Council Presidency Translator Sets New Records

by Tilde

Upcoming Events

See All
  1. Memsource MT Post-Editing Pricing Models Webinar

    Pricing Models for MT Post-Editing Workshop

    by Memsource

    · February 3

    Hear a panel of innovative localization professionals share different approaches for MT post-editing pricing.

    More info FREE

Featured Companies

See all
Text United

Text United

Memsource

Memsource

Wordbank

Wordbank

Protranslating

Protranslating

Seprotec

Seprotec

Versacom

Versacom

SDL

SDL

Smartling

Smartling

Lingotek

Lingotek

XTM International

XTM International

Smartcat

Smartcat

Translators without Borders

Translators without Borders

STAR Group

STAR Group

memoQ Translation Technologies

memoQ Translation Technologies

Advertisement

Popular articles

Why Netflix Shut Down Its Translation Portal Hermes

Why Netflix Shut Down Its Translation Portal Hermes

by Esther Bond

The Slator 2020 Language Service Provider Index

The Slator 2020 Language Service Provider Index

by Slator

Top Language Industry Quotes of 2020

Top Language Industry Quotes of 2020

by Monica Jamieson

SlatorPod: The Weekly Language Industry Podcast

connect with us

footer logo

Slator makes business sense of the language services and technology market.

Our Company

  • Support
  • About us
  • Terms & Conditions
  • Privacy Policy

Subscribe to the Slator Weekly

Language Industry Intelligence
In Your Inbox. Every Friday

© 2021 Slator. All rights reserved.

Sign up to the Slator Weekly

Join over 13,000 subscribers and get the latest language industry intelligence every Friday

Your information will never be shared with third parties. No Spam.